Analysts Set Celcuity Inc. (NASDAQ:CELC) Target Price at $29.17

Celcuity Inc. (NASDAQ:CELC) has earned a consensus recommendation of “Buy” from the seven research firms that are currently covering the firm, MarketBeat.com reports. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $29.17.

Several brokerages have commented on CELC. Needham & Company LLC reissued a “buy” rating and set a $23.00 price objective on shares of Celcuity in a research report on Friday, November 15th. Stifel Nicolaus lifted their price target on shares of Celcuity from $39.00 to $42.00 and gave the company a “buy” rating in a research report on Monday, October 7th. Finally, HC Wainwright reissued a “buy” rating and set a $27.00 price objective on shares of Celcuity in a research note on Friday, November 15th.

Hedge Funds Weigh In On Celcuity

A number of hedge funds have recently bought and sold shares of the company. nVerses Capital LLC bought a new position in Celcuity in the 3rd quarter valued at approximately $33,000. Prospera Private Wealth LLC purchased a new position in shares of Celcuity in the third quarter worth $35,000. Values First Advisors Inc. bought a new position in shares of Celcuity during the third quarter valued at $86,000. Quest Partners LLC boosted its position in shares of Celcuity by 31.3% during the second quarter. Quest Partners LLC now owns 5,788 shares of the company’s stock valued at $95,000 after buying an additional 1,379 shares during the last quarter. Finally, SG Americas Securities LLC purchased a new stake in shares of Celcuity during the third quarter valued at $119,000. Institutional investors own 63.33% of the company’s stock.

Celcuity Trading Up 4.4 %

CELC opened at $13.08 on Friday. The company has a quick ratio of 10.36, a current ratio of 10.35 and a debt-to-equity ratio of 0.65. Celcuity has a 52 week low of $11.51 and a 52 week high of $22.19. The stock has a market cap of $485.66 million, a PE ratio of -5.01 and a beta of 0.74. The business has a 50 day moving average of $13.90 and a 200-day moving average of $15.35.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.